Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
Alexandre DuongChantale SimardYi Le WangDavid WilliamsonAmélie MarsotPublished in: Antibiotics (Basel, Switzerland) (2021)
This review showed models developed for amikacin, from 2015 until now, and for gentamicin and tobramycin from the past decades. Despite the growing challenges of external evaluation, the latter should be more considered during model development. Further research including new covariates, additional simulated dosing regimens, and external validation should be considered to better understand aminoglycoside pharmacokinetics in ICU patients.